Founded in Prague, Czech Republic, Sotio is a biotechnology company dedicated to developing next-generation immunotherapies for cancer treatment. The company focuses on creating potent therapies based on activated dendritic cells, aiming to provide safer and more effective treatment options for various solid tumor types. Sotio's robust pipeline includes both internally developed and in-licensed candidates, underscoring its commitment to advancing clinical development in the oncology space.
Sotio has garnered attention through its innovative approach and significant contributions to cancer immunotherapy. The company has attracted notable investors and industry experts, enhancing its research and development capabilities. With a strong emphasis on translating scientific discoveries into tangible patient benefits, Sotio has made impactful strides in the biotech sector, positioning itself as a key player in the fight against cancer.
